For research use only. Not for therapeutic Use.
Flotetuzumab（Cat No.:I042099）is an investigational bispecific monoclonal antibody designed to target two distinct proteins: CD123 and CD3. CD123 is overexpressed on leukemia and other hematologic cancer cells, while CD3 is a component of T-cells, a crucial part of the immune system. By binding to both CD123 and CD3, flotetuzumab aims to redirect T-cells to target and kill cancer cells, enhancing the body’s immune response against the tumor. It is being evaluated in clinical trials, primarily for acute myeloid leukemia (AML), to assess its safety, efficacy, and potential in improving cancer treatment outcomes.
| Catalog Number | I042099 |
| CAS Number | 1664355-28-5 |
| Purity | ≥95% |
